Gaurav Sutrave

Gaurav Sutrave serves as a Clinical Lecturer within the Faculty of Medicine and Health at the University of Sydney, conducting research at the Westmead Institute for Medical Research. His work centers on developing cellular therapies to combat infections and malignancies in immunocompromised patients, particularly following hematopoietic stem cell transplantation.

His research portfolio spans:

• Genetic engineering of T-cells using transposon systems (piggyBac)
• Pathogen-specific T-cell therapies for viral/fungal infections
• CAR-T cell development for hematologic malignancies
• Safety optimization of adoptive immunotherapies
• Clinical translation of cellular products

Analysis of his publication history reveals consistent innovation in T-cell engineering, with recent focus shifting toward combinatorial approaches targeting both infection and cancer relapse. His 2022-2024 work demonstrates growing emphasis on transposon-based systems and real-world clinical applications across Australian healthcare settings.

Dr. Sutrave currently mentors PhD candidate Deekshitha DHULIPATI on transgenic T-cell development for fungal infections in hematologic cancer patients. He secured a 2025 Department of Health grant (COMITTAL34) investigating co-administration of malignancy- and infection-specific T-cells after stem cell transplant for acute leukemia. His clinical collaborations span multiple Sydney hospitals including Westmead and Royal Prince Alfred.

Within the Westmead Institute for Medical Research, he contributes to the Cellular Therapies Group focusing on GMP-compliant T-cell manufacturing and translational immunology studies. His work bridges laboratory engineering of cellular products with clinical implementation in high-risk transplant recipients.